Xultophy led to greater treatment satisfaction in people with type 2 diabetes compared to multiple daily injections, a new study reveals.
More participants on the DUAL VII trial preferred to stay on Xultophy treatment compared to therapy with bolus and basal injections, and had improvements in mental health.

Xultophy is a once-daily single combination injection of Tresiba (long-acting insulin degludec) and Victoza (liraglutide), a GLP-1 agonist. The drug, developed by Novo Nordisk, is designed to treat people with type 2 diabetes who’ve been unable to control blood sugar levels on other treatments.
Researchers monitored 506 adults with type 2 diabetes from 12 countries, who were either assigned Xultophy or basal-bolus treatment for 26 weeks. Prior to the study all participants had poorly controlled blood sugar levels on Lantus (insulin glargine) and metformin.
The participants were asked to complete a questionnaire after the trial to assess patient-related outcomes (PROs). Xultophy was significantly associated with better experiences for mental health, while other improvements included treatment burden and compliance.
Xultophy led to equal reductions in HbA1c, lower rates of hypoglycemia, fewer injections per day and greater weight loss, compared to those on multiple daily injections.
Mads Krogsgaard Thomse, executive vice president and chief science officer of Novo Nordisk, said: “Living with diabetes is a complex situation in itself, and the treatment should not add to this. We are very pleased to see that Xultophy not only helps people with type 2 diabetes reach their blood glucose targets while reducing the risk of hypoglycemia and helping them to lose weight, but does this in a simple way.”
The findings have been presented at the 2017 International Diabetes Federation Congress in Abu Dhabi, UAE.
Editor’s note: People experiencing difficulty controlling their diabetes can lower blood glucose levels, achieve weight loss and reduce dependency on medication by making healthy, sustainable lifestyle changes. Users of our Low Carb Program have been able to reduce medication needs and improve their quality of life by eating real, natural food.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…